GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (NAS:CAPR) » Definitions » Book Value per Share

Capricor Therapeutics (Capricor Therapeutics) Book Value per Share : $0.73 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Capricor Therapeutics Book Value per Share?

Capricor Therapeutics's book value per share for the quarter that ended in Dec. 2023 was $0.73.

During the past 12 months, Capricor Therapeutics's average Book Value Per Share Growth Rate was 55.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -19.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -17.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Capricor Therapeutics was 1.10% per year. The lowest was -154.90% per year. And the median was -47.45% per year.

Capricor Therapeutics's current price is $5.365. Its book value per share for the quarter that ended in Dec. 2023 was $0.73. Hence, today's PB Ratio of Capricor Therapeutics is 7.39.

During the past 13 years, the highest P/B Ratio of Capricor Therapeutics was 1486.96. The lowest was 0.82. And the median was 4.07.


Capricor Therapeutics Book Value per Share Historical Data

The historical data trend for Capricor Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Book Value per Share Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.31 1.37 1.30 0.47 0.73

Capricor Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.25 0.11 -0.07 0.73

Competitive Comparison of Capricor Therapeutics's Book Value per Share

For the Biotechnology subindustry, Capricor Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's PB Ratio falls into.



Capricor Therapeutics Book Value per Share Calculation

Capricor Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(22.60-0.00)/31.15
=0.73

Capricor Therapeutics's Book Value Per Share for the quarter that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(22.60-0.00)/31.15
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Capricor Therapeutics  (NAS:CAPR) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Capricor Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Capricor Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Capricor Therapeutics (Capricor Therapeutics) Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
Executives
David B Musket director C/O CONOR MEDSYSTEMS, INC., 1003 HAMILTON COURT, MENLO PARK CA 94025
Collier Earl M Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Paul Gisbert Auwaerter director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Mike Kelliher director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Philip J Gotwals director C/O CAPRICOR THERAPEUTICS, INC., 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Xavier Avat officer: CHIEF BUSINESS OFFICER 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO CA 92121
Karimah Es Sabar director C/O 8840 WILSHIRE BOULEVARD, 2ND FLOOR, BEVERLY HILLS CA 90211
Linda Marban director, officer: CHIEF EXECUTIVE OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Dunbar George W Jr director C/O COMPETITIVE TECHNOLOGIES, INC., 777 COMMERCE DRIVE, SUITE 100, FAIRFIELD CT 06825
Karen Krasney officer: EVP, GENERAL COUNSEL C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Anthony Bergmann officer: CHIEF FINANCIAL OFFICER C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Louis Manzo director C/O CAPRICOR THERAPEUTICS, INC., 8840 WILSHIRE BLVD., 2ND FLOOR, BEVERLY HILLS CA 90211
Cedars Sinai Medical Center 10 percent owner 8700 BEVERLY BLVD, LOS ANGELES CA 90048-1865
St. John Edward A. 10 percent owner 2560 LORD BALTIMORE DRIVE, BALTIMORE MD 21244
Leland Gershell officer: Chief Financial Officer C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., STE 306, NEW YORK NY 10022

Capricor Therapeutics (Capricor Therapeutics) Headlines

From GuruFocus

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

By GuruFocusNews GuruFocusNews 07-04-2022